# Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules

> **NCT02841150** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 102 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** IMBRUVICA (Treatment A)
- **DRUG:** Ibrutinib (Treatment B)

## Key facts

- **NCT ID:** NCT02841150
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2018-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02841150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02841150, "Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02841150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*